



UNIVERSITY OF LEEDS

This is a repository copy of *Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case-control study*.

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/159152/>

Version: Accepted Version

Article:

Quattrone, D, Ferraro, L, Tripoli, G et al. (39 more authors) (2020) Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case-control study. *Psychological Medicine*. ISSN 0033-2917

<https://doi.org/10.1017/s0033291720000082>

This article has been published in a revised form in *Psychological Medicine* <https://doi.org/10.1017/S0033291720000082>. This version is free to view and download for private research and study only. Not for re-distribution, re-sale or use in derivative works.
© The Author(s) 2020. Published by Cambridge University Press

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

1 **Daily use of high potency cannabis is associated with more positive**
2 **symptoms in first episode psychosis patients: the EU-GEI case-control study**

3
4
5 *Diego Quattrone, MD^{1,2,3,†}; Laura Ferraro, PhD⁴; Giada Tripoli, MsC⁵; Caterina La*
6 *Cascia, PhD⁴; Harriet Quigley, MD⁵; Andrea Quattrone, MsC⁶; Hannah Jongsma,*
7 *PhD⁷; Simona Del Peschio, MsC⁸; Giusy Gatto, MsC⁸; EU-GEI group[‡]; Charlotte*
8 *Gayer-Anderson, PhD⁹; Peter B. Jones, MD, PhD^{10,11}; James B. Kirkbride, PhD⁷,*
9 *Daniele La Barbera, MD⁴; Ilaria Tarricone, MD, PhD¹²; Sarah Tosato, MD, PhD¹³;*
10 *Antonio Lasalvia, MD, PhD¹³; Andrei Szöke, MD, PhD¹⁴; Celso Arango, MD, PhD¹⁵;*
11 *Miquel Bernardo, MD, PhD¹⁶; Julio Bobes, MD, PhD¹⁷; Cristina Marta Del Ben, MD,*
12 *PhD¹⁸; Paulo Rossi Menezes, MD, PhD¹⁸; Pierre-Michel Llorca, MD, PhD¹⁹; Jose Luis*
13 *Santos, MD, PhD²⁰; Julio Sanjuán, MD, PhD²¹; Andrea Tortelli, MD, PhD²²; Eva*
14 *Velthorst, PhD^{23,24}; Lieuwe de Haan, MD, PhD²³; Bart P.F. Rutten, MD, PhD²⁵;*
15 *Michael T. Lynskey, PhD²⁶; Tom P. Freeman, PhD^{26,27}; Pak C. Sham, MD, PhD^{28,29};*
16 *Alistair Cardno, PhD³⁰; Evangelos Vassos, MD, PhD¹; Jim van Os, MD, PhD^{25,31}; Craig*
17 *Morgan, PhD⁹; Ulrich Reininghaus, PhD^{3,9,25}; Cathryn M. Lewis, PhD¹; Robin M.*
18 *Murray, MD, FRS^{2,5} and Marta Di Forti, MD, PhD^{1,2}*

19
20 ¹ Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry,
21 Psychology and Neuroscience, King's College London, London, United Kingdom, SE5
22 8AF

23 ² National Institute for Health Research (NIHR) Maudsley Biomedical Research
24 Centre, South London and Maudsley NHS Foundation Trust, King's College London,
25 London, UK

26 ³ Central Institute of Mental Health, Medical Faculty Mannheim, University of
27 Heidelberg, Mannheim, Germany

28 ⁴ Department of Experimental Biomedicine and Clinical Neuroscience, University of
29 Palermo, Via G. La Loggia 1, 90129 Palermo, Italy

30 ⁵ Department of Psychosis Studies, Institute of Psychiatry, Psychology and
31 Neuroscience, King's College London, De Crespigny Park, Denmark Hill, London,
32 United Kingdom SE5 8AF

33 ⁶ Department of Chemical, Biological, Pharmaceutical and Environmental Sciences,
34 University of Messina, 98100, Messina, Italy

35 ⁷ Psylife Group, Division of Psychiatry, University College London, 6th Floor, Maple
36 House, 149 Tottenham Court Road, London, W1T 7NF

37 ⁸ University of Bologna

38 ⁹ Department of Health Service and Population Research, Institute of Psychiatry,
39 Psychology and Neuroscience, King's College London, De Crespigny Park, Denmark
40 Hill, London, United Kingdom, SE5 8AF

41 ¹⁰ Department of Psychiatry, University of Cambridge, Herchel Smith Building for Brain
42 & Mind Sciences, Forvie Site, Robinson Way, Cambridge, CB2 0SZ, United Kingdom

43 ¹¹ CAMEO Early Intervention Service, Cambridgeshire & Peterborough NHS
44 Foundation Trust, Cambridge, CB21 5EF, UK

45 ¹² Department of Medical and Surgical Science, Psychiatry Unit, Alma Mater
46 Studiorum Università di Bologna, Viale Pepoli 5, 40126 Bologna, Italy

47 ¹³ Section of Psychiatry, Department of Neuroscience, Biomedicine and Movement,
48 University of Verona, Piazzale L.A. Scuro 10, 37134 Verona, Italy

49 ¹⁴ INSERM, U955, Equipe 15, 51 Avenue de Maréchal de Lattre de Tassigny, 94010
50 Créteil, France

51 ¹⁵ Child and Adolescent Psychiatry Department, Institute of Psychiatry and Mental
52 Health, Hospital General Universitario Gregorio Marañón, School of Medicine,
53 Universidad Complutense, IiSGM, CIBERSAM, C/Doctor Esquerdo 46, 28007 Madrid,
54 Spain

55 ¹⁶ Barcelona Clinic Schizophrenia Unit, Neuroscience Institute, Hospital Clinic of
56 Barcelona, Department of Medicine, University of Barcelona, IDIBAPS, CIBERSAM,
57 Barcelona, Spain

58 ¹⁷ Faculty of Medicine and Health Sciences - Psychiatry, Universidad de Oviedo, ISPA,
59 INEUROPA. CIBERSAM. Oviedo, Spain

60 ¹⁸ Department of Preventative Medicine, Faculdade de Medicina FMUSP, University
61 of São Paulo, São Paulo, Brazil

62 ¹⁹ EA 7280 Npsydo, Université Clermont Auvergne, Clermont-Ferrand, France

63 ²⁰ Department of Psychiatry, Servicio de Psiquiatría Hospital "Virgen de la Luz,"
64 Cuenca, Spain

65 ²¹ Department of Psychiatry, School of Medicine, Universidad de Valencia, Centro de
66 Investigación Biomédica en Red de Salud Mental, Valencia, Spain

67 ²² Etablissement Public de Santé Maison Blanche, Paris, France

68 ²³ Department of Psychiatry, Early Psychosis Section, Academic Medical Centre,
69 University of Amsterdam, Amsterdam, The Netherlands

70 ²⁴ Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New
71 York

72 ²⁵ Department of Psychiatry and Neuropsychology, School for Mental Health and
73 Neuroscience, South Limburg Mental Health Research and Teaching Network,
74 Maastricht University Medical Centre, P.O. Box 616, 6200 MD Maastricht, The
75 Netherlands

76 ²⁶ National Addiction Centre, Institute of Psychiatry, Psychology & Neuroscience,
77 King's College London, 4 Windsor Walk, London, SE5 8BB, UK

78 ²⁷ Department of Psychology, University of Bath, 10 West, Bath, BA2 7AY, UK

79 ²⁸ Department of Psychiatry, the University of Hong Kong, Hong Kong

80 ²⁹ Centre for Genomic Sciences, Li KaShing Faculty of Medicine, The University of
81 Hong Kong, Hong Kong

82 ³⁰ Academic Unit of Psychiatry and Behavioural Sciences, University of Leeds, Leeds,
83 United Kingdom

84 ³¹ Brain Centre Rudolf Magnus, Utrecht University Medical Centre, Utrecht, The
85 Netherlands

86

87 **Word count (Main text): 3,488 words**

88

89 †Correspondence to: Dr Diego Quattrone, diego.quattrone@kcl.ac.uk, Tel.
90 00442078485271, Social, Genetic and Developmental Psychiatry Centre, Institute of
91 Psychiatry, Psychology and Neuroscience, King's College London, London, United
92 Kingdom, SE5 8AF

93 ‡For a full list of the EU-GEI group authors, see below Acknowledgments

94

95 **Abstract**

96 **Background:** Daily use of high potency cannabis has been reported to carry a high
97 risk for psychotic disorder. However, the evidence is mixed on whether any pattern of
98 cannabis use is associated with a particular symptomatology in first episode psychosis
99 (FEP) patients.

100 **Method:** We analysed data from 901 patients and 1235 controls recruited across six
101 countries, as part of the European Network of National Schizophrenia Networks
102 Studying Gene-Environment Interactions (EU-GEI) study. We used item response
103 modelling to estimate two bifactor models, which included general and specific
104 dimensions of psychotic symptoms in patients and psychotic experiences in controls.
105 The associations between these dimensions and cannabis use were evaluated using
106 linear mixed effects models analyses.

107 **Results:** In patients, there was a linear relationship between the positive symptom
108 dimension and the extent of lifetime exposure to cannabis, with daily users of high
109 potency cannabis having the highest score ($B=0.35$; 95%CI 0.14 to 0.56). Moreover,
110 negative symptoms were more common among patients who never used cannabis
111 compared with those with any pattern of use ($B=-0.22$; 95%CI -0.37 to -0.07). In
112 controls, psychotic experiences were associated with current use of cannabis but not
113 with the extent of lifetime use. Neither patients nor controls presented differences in
114 depressive dimension related to cannabis use.

115 **Conclusions:** Our findings provide the first large scale evidence that first episode
116 psychotic patients with a history of daily use of high potency cannabis present with
117 more positive and less negative symptoms than those who never used cannabis or
118 used low potency types.

119

120 **Keywords**

121 Cannabis use; symptom dimensions; psychopathology; psychotic experiences;
122 cannabis-associated psychosis

123

124 **Introduction**

125 There is compelling evidence suggesting that cannabis use is associated with
126 psychotic disorders (Marconi *et al.*, 2016). However, it is unclear whether cannabis
127 use is a ‘modifier’ factor for psychotic disorders, which affects symptom presentation.

128 The existence of a pattern of psychotic symptomatology particularly associated with
129 cannabis has been described in several case series (Walter Bromberg, 1934, Talbott
130 and Teague, 1969, Spencer, 1971, Bernhardson and Gunne, 1972, Chopra and
131 Smith, 1974). Nevertheless, case and cohort studies have found mixed results as to
132 whether (Negrete *et al.*, 1986, Peralta and Cuesta, 1992, Bersani *et al.*, 2002, Green
133 *et al.*, 2004, Grech *et al.*, 2005, Addington and Addington, 2007, Foti *et al.*, 2010,
134 Ringen *et al.*, 2016, Seddon *et al.*, 2016) or not (Thornicroft *et al.*, 1992, Stirling *et al.*,
135 2005, Dubertret *et al.*, 2006, Boydell *et al.*, 2007, van Dijk *et al.*, 2012, Tosato *et al.*,
136 2013, Barrowclough *et al.*, 2015) psychotic patients using cannabis present with more
137 positive symptoms than those not using cannabis. Moreover, there is mixed evidence
138 of any relationship between cannabis use and negative symptoms in psychosis. Some
139 reports suggest fewer negative symptoms in psychotic patients that use cannabis
140 (Peralta and Cuesta, 1992, Bersani *et al.*, 2002, Green *et al.*, 2004), which is
141 consistent with having enough social skills to obtain the substance (Murray *et al.*,
142 2017). However, this association has not been confirmed in other studies (Grech *et*
143 *al.*, 2005, Seddon *et al.*, 2016) and others even reported a positive association (Ringen
144 *et al.*, 2016).

145 These inconsistencies might be explained by differences in study design and methods.
146 For example, only a few findings were based on first episode psychosis (FEP) patients
147 (Grech *et al.*, 2005, Addington and Addington, 2007, Tosato *et al.*, 2013, Seddon *et*
148 *al.*, 2016), which minimize selection and recall bias, and the confounding effect of
149 antipsychotic drugs on symptoms. In addition, a metaanalysis of longitudinal studies
150 concluded that most results lacked sufficient power to detect an effect of cannabis on
151 symptoms, or inadequately controlled for potential confounders (Zammit *et al.*, 2008).
152 Furthermore, although a few studies included information on frequency of use, all
153 failed to obtain detailed information on the lifetime pattern of cannabis use, especially
154 on the type and strength of cannabis used. Of note, potent cannabis varieties, with
155 high concentrations of Delta-9-Tetrahydrocannabinol (Δ 9-THC), have been
156 associated with the most harm to mental health (Di Forti *et al.*, 2015, Freeman *et al.*,
157 2018) and, in recent years, these potent types have become more available worldwide
158 (ElSohly *et al.*, 2016, Potter *et al.*, 2018, Freeman *et al.*, 2019). Finally, no studies
159 have used factor analysis of observed symptoms to evaluate to what extent cannabis
160 use is a factor influencing the clinical heterogeneity of psychosis.

161 On the other hand, in the general population there are consistent findings regarding
162 the association between cannabis use and psychotic experiences (Ragazzi *et al.*,
163 2018). However, most studies had limited geographical coverage and the examined
164 population was scarcely representative of the population at risk of psychosis (Ragazzi
165 *et al.*, 2018).

166 In this study, we set out to clarify the association between detailed patterns of cannabis
167 use and transdiagnostic symptom dimensions in a large multinational FEP sample. In
168 addition, we examine the association between detailed patterns of cannabis use and

169 subclinical symptom dimensions in a large sample of controls representative of the
170 population at risk in each catchment area.

171 Specifically, we sought to test the hypotheses that: (1) positive psychotic symptoms
172 are more common among FEP patients with more frequent lifetime use of cannabis
173 and greater exposure to use of high potency varieties; (2) positive psychotic
174 experiences are more common in population controls with a recent use of cannabis,
175 who would be more resilient to the long-term effects of cannabis; (3) negative
176 symptoms are more common among those patients who have never used cannabis.

177

178 **Methods**

179 **Study design and participants**

180 This analysis is based on the incidence and case-control study work package of the
181 EUropean network of national schizophrenia networks studying Gene-Environment
182 Interactions (EU-GEI).

183 FEP individuals were identified between 2010 and 2015 across six countries to
184 examine incidence rates of schizophrenia and other psychotic disorders (Jongsma *et*
185 *al.*, 2018), and symptomatology at psychosis onset (Quattrone *et al.*, 2019). For
186 examining risk factors, we sought to perform an extensive assessment on
187 approximately 1,000 FEP patients and 1,000 population-based controls during the
188 same time period.

189 Patients were included in the case-control study if they met the following criteria during
190 the recruitment period: (a) aged between 18 and 64 years; (b) presentation with a
191 clinical diagnosis for an untreated FEP, even if longstanding [International Statistical
192 Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10)
193 codes F20-F33]; (c) resident within the catchment area. Exclusion criteria were: (a)

194 previous contact with psychiatric services for psychosis; (b) psychotic symptoms
195 originating from an identified organic condition; and (c) transient psychotic symptoms
196 resulting from acute intoxication (ICD-10: F1x.5).

197 The recruitment of controls followed a mixture of random and quota sampling methods,
198 in order to achieve the best possible representativeness in age, sex, and ethnicity of
199 the population living in each catchment area. The identification process varied by site
200 and was based on locally available sampling frames, including mostly the use of lists
201 of all postal addresses and general practitioners' lists from randomly selected
202 surgeries. When these resources were not fully available, internet and newspapers
203 advertising were used to fill quotas. Exclusion criteria for controls were: (a) diagnosis
204 of a psychotic disorder; (b) ever having been treated for psychotic symptoms.

205 We analysed data from eleven catchment areas, including urban and less urban
206 populations (i.e. Southeast London, Cambridgeshire and Peterborough (England);
207 central Amsterdam, Gouda and Voorhout (the Netherlands); Bologna municipality, city
208 of Palermo (Italy); Paris [Val-de-Marne], Puy-de-Dôme (France); Madrid [Vallecas],
209 Barcelona (Spain); and Ribeirão Preto (Brazil). Further information on the case-control
210 sample and the recruitment strategies is included in the supplementary material.

211 **Measures**

212 Data on age, sex, and ethnicity were collected using a modified version of the Medical
213 Research Council Sociodemographic Schedule (Mallett, 1997). The OPERational
214 CRITeria (OPCRIT) system (McGuffin *et al.*, 1991) was used by centrally trained
215 investigators, whose reliability was assessed before and throughout the study ($k=0.7$),
216 to assess psychopathology in the first four weeks after the onset and generate
217 research-based diagnoses based on different diagnostic classification systems. The
218 Community Assessment of Psychic Experiences (CAPE) (Stefanis *et al.*, 2002) was

219 administered to controls to self-report their psychotic experiences. The reliability of the
220 CAPE is good for all the languages spoken in the countries forming part of the EU-
221 GEI study (<http://cape42.homestead.com>).

222 A modified version of the Cannabis Experience Questionnaire (CEQ_{EU-GEI}) (Di Forti *et*
223 *al.*, 2009) was used by investigators to collect extensive information on the patterns of
224 use of cannabis and other drugs. We used six measures of cannabis use
225 (Supplementary Table S2), including a variable measuring specific patterns of
226 cannabis exposure by combining the frequency of use with the potency of cannabis.
227 As illustrated in the supplementary material, the cannabis potency variable was based
228 on the data published in the European Monitoring Centre for Drugs and Drug Addiction
229 (EMCDDA) (European Monitoring Centre for Drugs and Drug Addiction, 2013, Di Forti
230 *et al.*, 2019).

231 We selected confounders based on their possible association with cannabis use
232 and/or symptom dimensions. These included: sex; age; ethnicity; use of stimulants,
233 hallucinogens, ketamine, cocaine, crack, and novel psychoactive substances; current
234 use of cigarettes (smoking 10 cigarettes or more per day=1), and current use of alcohol
235 (drinking 10 alcohol units or more per week=1).

236 **Statistical analysis**

237 **Dimensions of psychotic symptoms in patients and psychotic experiences in** 238 **controls**

239 Data from OPCRIT and CAPE were analysed using multidimensional item response
240 modelling in *Mplus*, version 7.4 (Muthén and Muthén, 2012), to estimate two bifactor
241 models, based on the associations among observer ratings of psychotic symptoms in
242 patients and self-ratings of psychotic experiences in controls. This methodology is
243 described in full in our EU-GEI paper on symptom dimensions in FEP patients

244 (Quattrone *et al.*, 2019), and it was likewise applied to psychotic experiences in
245 population controls. Briefly, CAPE items were dichotomized as 0 'absent' or 1
246 'present'. In order to ensure sufficient covariance coverage for item response
247 modelling, we used items with a valid frequency of 'present' $\geq 10\%$ in our sample, and
248 we excluded items with low correlation values ($<.3$) based on the examination of the
249 item correlation matrix. As in the previous analysis in patients, the bifactor solution
250 was compared with other solutions (i.e., unidimensional, multidimensional, and
251 hierarchical models) using Log-Likelihood (LL), Akaike Information Criterion (AIC),
252 Bayesian Information Criterion (BIC), and Sample-size Adjusted BIC (SABIC) as
253 model fit statistics. Path diagrams that illustrate these models are presented in
254 Supplementary Figure S1. Reliability and strength indices such as McDonald's omega
255 (ω) (Rodriguez *et al.*, 2016), omega hierarchical (ω_H) (Rodriguez *et al.*, 2016), and
256 index H (Hancock and Mueller, 2001), were computed to determine: 1) the proportion
257 of common variance accounted by general and specific symptom dimensions; 2) the
258 proportion of reliable variance accounted by the general dimension not unduly affected
259 by the specific dimensions; 3) the proportion of reliable variance accounted for by each
260 specific dimension not unduly affected by the general and all the other specific
261 dimensions; 4) the overall reliability and replicability of the bifactor construct of
262 psychosis-like experiences. Finally, we generated factor scores for one general
263 psychotic experience dimension and three specific dimensions of positive, negative,
264 and depressive psychotic experiences.

265 For patients, we used the previously generated factor scores for one general
266 psychosis dimension and five specific dimensions of positive, negative, disorganised,
267 manic, and depressive symptoms (Quattrone *et al.*, 2019).

268 **Symptom dimensions and cannabis use**

269 We evaluated the relationship between psychotic symptom dimensions in patients, or
270 psychotic experience dimensions in controls, and cannabis use using linear mixed
271 effects models in STATA14 (StataCorp, 2015). We specifically modelled symptom
272 dimension scores as a function of each of the six measures of cannabis use. We then
273 evaluated the combined effect of frequency of use and potency of cannabis. To
274 account for the non-independence of symptom profiles of subjects assessed within
275 the same country (for example, due to cultural similarities), and for the potential within-
276 site correlation (for example, due to context factors), we fitted a three-level mixed
277 model, where the random effect encompassed two levels of random intercepts: one
278 due to the countries, and another due to the sites within the countries. Finally, we used
279 the Benjamini-Hochberg (B-H) procedure to reduce the false discovery rate, which we
280 set at 5%.

281

282 **Results**

283 **Sample characteristics**

284 We analysed data from 901 FEP patients and 1,235 controls. The main socio-
285 demographic characteristics and history of substance misuse of patients and controls
286 are presented in Supplementary Table S1. Supplementary Tables S3 and S5 show
287 the sample prevalence of psychotic experiences in controls and of psychotic
288 symptoms in patients.

289 **Bifactor model of psychotic experiences in controls**

290 Supplementary Table S4 shows that, as in our previous analysis of the OPCRIT items
291 (Quattrone *et al.*, 2019), the bifactor model provided the best fit for the CAPE items,
292 as illustrated by AIC, BIC and SABIC substantially lower compared with competing
293 models. This solution explained 60% of the unique variance. In addition, Figure 1

294 shows that, within the bifactor model, the explained variance was due to individual
295 differences mostly on the general psychotic experience dimension. This is illustrated
296 by the relative omega coefficient, which, for example, showed that 85% of the reliable
297 variance was due to the general dimension when partitioning out the variability in
298 scores due to the specific dimensions. Moreover, factor loadings of moderate to high
299 magnitude were observed for most items on the general psychotic experience
300 dimension, whereas factor loadings of a smaller magnitude were observed for the
301 specific dimensions (Figure 1). Consistently, the index *H*, which is a measure of the
302 construct reliability and replicability across studies (Hancock and Mueller, 2001), was
303 very high for the general dimension (0.92), moderate for positive (0.78) and negative
304 (0.71) dimensions and lower for the depressive dimension (0.41).

305

306 **Symptom dimensions in patients by pattern of cannabis use**

307 Models' results are presented in Table 1.1 which shows that:

308 1) There were no differences in the distribution of positive symptoms according to early
309 age at first use (≤ 15 years old), nor, after B-H correction, according to ever or current
310 use of cannabis. However, positive symptoms were more common among patients
311 who spent more than 20 euros per week on cannabis ($B=0.3$; 95%CI 0.11 to 0.48;
312 $p=0.001$).

313 2) Fewer negative symptoms were observed among those patients who used
314 cannabis at least once compared with those who never tried ($B=-0.22$; 95%CI -0.37 to
315 -0.07; $p=0.004$). Early age at first use and current use of cannabis was not associated
316 with negative symptomatology.

317 3) Manic symptoms were more frequent among patients who had ever used cannabis
318 ($B=0.22$; 95%CI 0.08 to 0.36; $p=0.002$).

319 4) There were no differences in the distribution of the scores on the depressive,
320 disorganization and general psychosis dimensions according to any measure of
321 cannabis use.

322

323

324 **Psychotic experience dimensions in population controls by patterns of** 325 **cannabis use**

326 Models' results are presented in Table 1.2, which shows that:

327 1) There were no differences in the distribution of positive psychotic experiences
328 according to ever use of cannabis or early age at first use (≤ 15 years old). However,
329 positive psychotic experiences were more commonly reported by subjects who
330 currently used cannabis ($B=0.33$; 95%CI 0.15 to 0.51; $p<0.001$) and who spent more
331 than 20 euros per week on cannabis ($B=0.39$; 95%CI 0.09 to 0.69; $p=0.011$).

332 2) There were no differences in the distribution of the depressive and negative
333 experiences in population controls according to cannabis use.

334

335 **Symptom dimensions by frequency of use and potency of cannabis**

336 The independent effects of frequency of use and potency of cannabis is reported in
337 Supplementary Tables S6.1 and S6.2, and Supplementary Figure S2, showing that,
338 only in patients, positive symptoms were more common in those who used cannabis
339 on a daily basis and exposed to high potency varieties

340 Testing the combined 'type-frequency' variable in patients, we found evidence of a
341 linear relationship between the positive symptom dimension and the extent of
342 exposure to cannabis, with daily users of high potency cannabis showing the highest
343 score ($B=0.35$; 95%CI 0.14 to 0.56; $p=0.001$). Therefore, we introduced a contrast
344 operator and plotted the exposure-response relationship for positive symptoms

345 (Figure 2), by comparing the predictive margins of the adjusted mean of each group
346 against the grand adjusted mean of all groups. Figure 2 shows that the adjusted mean
347 for daily users of high potency cannabis was 0.2 units greater than the grand adjusted
348 mean. Moreover, the adjusted means for the groups who never or rarely used
349 cannabis were respectively 0.16 or 0.18 units lower than the grand adjusted mean.

350 A negative relationship between the negative symptom dimension score and patterns
351 of cannabis use was also observed in patients. Figure 3 shows that patients with
352 psychosis who never used cannabis had more negative symptoms either compared
353 with the grand adjusted mean or with any pattern of cannabis use.

354

355 **Discussion**

356 **Principal findings**

357 This is the first multinational study analysing data on the potency of the cannabis used
358 by FEP patients to investigate a dose effect relationship between cannabis use and
359 dimensions of symptoms, and also its effect on dimensions of psychotic experiences
360 in population controls. We provide the first evidence that: 1) in patients, a positive
361 correlation exists between the extent of premorbid cannabis use and the score on the
362 positive symptom dimension, with daily users of high potency cannabis showing the
363 most positive symptoms at FEP; 2) psychotic experiences in non-clinical populations
364 are associated with current use of cannabis but are independent of the extent of
365 lifetime exposure to cannabis; 3) negative symptoms at FEP are more common in
366 patients who have never tried cannabis; 4) depressive symptoms are independent of
367 any pattern of use of cannabis.

368 **Limitations**

369 Our findings must be considered in the context of two main limitations. First, individual
370 data on patterns of cannabis use are not validated with biological samples. However,

371 biological tests are not considered the gold standard method for such a validation
372 (Large *et al.*, 2012) and would not allow one to ascertain the extent of cannabis use
373 over the years (Taylor *et al.*, 2017). Moreover, studies combining self-report and
374 laboratory data support the reliability of subjects in reporting the type of cannabis they
375 use (Wolford *et al.*, 1999, Freeman *et al.*, 2014). Second, we did not take into account
376 the cannabidiol (CBD) contribution to the potency variable, as official data on its
377 content in the different cannabis varieties were not available in most study sites; CBD
378 might counterbalance $\Delta 9$ -THC effects and minimise both psychotic experiences
379 (Schubart *et al.*, 2011) and symptoms (McGuire *et al.*, 2018).

380 **Comparison with previous research**

381 We extend previous research on cannabis and psychotic symptoms to a multinational
382 sample confirming the association between cannabis use and positive symptoms of
383 FEP (Ringen *et al.*, 2016, Seddon *et al.*, 2016). Our results are in line with Schoeler *et*
384 *al.* (2016), who carefully scrutinised the literature on the effect of continuation of
385 cannabis use after FEP, concluding that this would be associated with a more severe
386 positive symptomatology (Schoeler *et al.*, 2016). That said, any comparison with
387 previous research is limited by the lack of information on frequency and potency in all
388 the previous studies along with subjects' exposure to more potent varieties of cannabis
389 in recent years (Potter *et al.*, 2018). In this respect, we firstly provide some evidence
390 that cannabis affects positive symptoms in a dose response manner, further
391 supporting the converging epidemiological and experimental evidence that the use of
392 cannabis with high content of $\Delta 9$ -THC has a more detrimental effect than other
393 varieties (Di Forti *et al.*, 2009, Morrison *et al.*, 2009, Freeman *et al.*, 2018).

394 We also report evidence in a multinational FEP sample of an association between
395 lifetime cannabis use and fewer negative symptoms, the latter often considered as a

396 marker of greater neurodevelopmental impairment in psychotic subjects. Two opposite
397 interpretations should be discussed.

398 First, some authors have suggested that people with a psychotic disorder might use
399 cannabis as an attempt to self-medicate negative symptoms, and thus the observed
400 reduction in negative symptomatology would be an epiphenomenon due to the
401 cannabis intake itself (Peralta and Cuesta, 1992).

402 Second, psychotic disorders may be characterized by less neurodevelopmental
403 features when associated with cannabis use (Ruiz-Veguilla *et al.*, 2012, Ferraro *et al.*,
404 2013, Murray *et al.*, 2017, Ferraro *et al.*, 2019), hence FEP patients who do not initiate
405 to use cannabis would have more negative symptoms.

406 The lack of a dose dependency in our study appears to speak against the first and in
407 favour of the second possibility, as the difference holds between those who never
408 obtained cannabis and those who may have used it only once. Moreover, negative
409 symptoms would reduce the social and instrumental skills that were necessary to
410 obtain illegally cannabis and sustain its use in all the countries included in the study,
411 except Holland.

412 Last, we report that the cumulative exposure to cannabis does not impact on psychotic
413 experiences in controls. One could of course argue that the largest proportion of
414 subjects with the harmful pattern of cannabis use were patients. However, further
415 research is needed to look into plausible mechanisms of resilience to the
416 psychotogenic effect of cannabis as observed in our controls, who report psychotic
417 experiences if current users but do not seem to accumulate a risk over life time
418 cannabis use and develop psychotic disorders. Indeed, future studies should aim to:
419 1) investigate if and how genetic factors, plausibly regulating the endocannabinoid and
420 dopamine systems, pose a small subset of cannabis users at high risk of developing

421 a psychotic disorders with particular symptomatology; 2) clarify over the course of the
422 disorder whether or not differences in symptomatology between current and former
423 cannabis users may be related to residual cannabis effects.

424 **Implications**

425 The novelty of our study is based on our examination of data on lifetime frequency of
426 cannabis use and on the type of the cannabis used; high potency types are increasing
427 worldwide. For instance, a recent potency study revealed that in London, the high
428 potency type of cannabis called skunk has now taken up 96% of the street market
429 (Potter *et al.*, 2018). The EMCDDA has described a European cannabis market
430 characterised by potent varieties (European Monitoring Centre for Drugs and Drug
431 Addiction, 2013) like those present in Amsterdam coffee shops that can reach up to
432 39% of THC. Indeed, as daily use, and use of high potency cannabis, have been
433 associated both with greatest risk to develop psychotic disorders and to high rates of
434 psychotic disorders across Europe (Di Forti *et al.*, 2019), here we show that in FEP
435 patients daily use of high potency cannabis drives a high score on the positive
436 symptom dimension. Further research should aim to determine biological mechanisms
437 underlying how cannabis impacts on different clinical manifestations of psychosis.
438 Meanwhile, translating current findings into clinical practice, symptom dimension
439 scores can be used to stratify patients and develop secondary prevention schemes for
440 cannabis-associated psychosis.

441 442 **Financial support**

443 The work was supported by: Clinician Scientist Medical Research Council fellowship
444 (project reference MR/M008436/1) to MDF; the National Institute for Health
445 Research (NIHR) Collaboration for Leadership in Applied Health Research and Care
446 South London at King's College Hospital NHS Foundation Trust to DQ; DFG

447 Heisenberg professorship (no. 389624707) to UR. National Institute for Health
448 Research (NIHR) Biomedical Research Centre for Mental Health at South London
449 and Maudsley NHS Foundation Trust and King's College London. The views
450 expressed are those of the author(s) and not necessarily those of the NHS, the NIHR
451 or the Department of Health and Social Care.

452 The EU-GEI Project is funded by the European Community's Seventh Framework
453 Programme under grant agreement No. HEALTH-F2-2010-241909 (Project EU-GEI).

454 The Brazilian study was funded by the São Paulo Research Foundation under grant
455 number 2012/0417-0.

456 Funders were not involved in design and conduct of the study; collection,
457 management, analysis and interpretation of the data; preparation, review or approval
458 of the manuscript, and decision to submit the manuscript for publication.

459

460 **Acknowledgements**

461 *‡EU-GEI group authorship includes:*

462 Kathryn Hubbard¹, Stephanie Beards¹, Simona A. Stilo², Mara Parellada³, David
463 Fraguas³, Marta Rapado Castro³, Álvaro Andreu-Bernabeu³, Gonzalo López³, Mario
464 Matteis³, Emiliano González³, Manuel Durán-Cutilla³, Covadonga M. Díaz-Caneja³,
465 Pedro Cuadrado⁴, José Juan Rodríguez Solano⁵, Angel Carracedo⁶, Javier Costas⁶,
466 Emilio Sánchez⁷, Silvia Amoretti⁸, Esther Lorente-Rovira⁹, Paz Garcia-Portilla¹⁰,
467 Estela Jiménez-López¹¹, Nathalie Franke¹², Daniella van Dam¹², Fabian
468 Termorshuizen^{13,14}, Nathalie Franke¹³, Elsje van der Ven^{13,14}, Elles Messchaart¹⁴,
469 Marion Leboyer^{15,16,17,18}, Franck Schürhoff^{15,16,17,18}, Stéphane Jamain^{16,17,18}, Grégoire
470 Baudin^{15,16}, Aziz Ferchiou^{15,16}, Baptiste Pignon^{15,16,18}, Jean-Romain Richard^{16,18},
471 Thomas Charpeaud^{18,19,21}, Anne-Marie Tronche^{18,19,21}, Flora Frijda²², Giovanna

472 Marrazzo²³, Lucia Sideli²², Crocettarachele Sartorio^{22,23}, Fabio Seminerio²², Camila
473 Marcelino Loureiro^{24,25}, Rosana Shuhama^{24,25}, Mirella Ruggeri²⁶, Chiara Bonetto²⁶,
474 Doriana Cristofalo²⁶, Domenico Berardi²⁷, Marco Seri²⁷, Giuseppe D'Andrea²⁷,
475 Michael C O'Donovan²⁸, Alexander L Richards²⁸.

476 *Affiliations*

477 ¹ Department of Health Service and Population Research, Institute of Psychiatry,
478 King's College London, De Crespigny Park, Denmark Hill, London, United Kingdom,
479 SE5 8AF

480 ² Department of Psychosis Studies, Institute of Psychiatry, King's College London, De
481 Crespigny Park, Denmark Hill, London, United Kingdom SE5 8AF

482 ³ Department of Child and Adolescent Psychiatry, Hospital General Universitario
483 Gregorio Marañón, School of Medicine, Universidad Complutense, IISGM
484 (CIBERSAM), C/Doctor Esquerdo 46, 28007 Madrid, Spain

485 ⁴ Villa de Vallecas Mental Health Department, Villa de Vallecas Mental Health Centre,
486 Hospital Universitario Infanta Leonor / Hospital Virgen de la Torre, C/San Claudio 154,
487 28038 Madrid, Spain

488 ⁵ Puente de Vallecas Mental Health Department, Hospital Universitario Infanta Leonor
489 / Hospital Virgen de la Torre, Centro de Salud Mental Puente de Vallecas, C/Peña
490 Gorbea 4, 28018 Madrid, Spain

491 ⁶ Fundación Pública Galega de Medicina Xenómica, Hospital Clínico Universitario,
492 Choupana s/n, 15782 Santiago de Compostela, Spain

493 ⁷ Department of Psychiatry, Hospital General Universitario Gregorio Marañón, School
494 of Medicine, Universidad Complutense, IISGM (CIBERSAM), C/Doctor Esquerdo 46,
495 28007 Madrid, Spain

496 ⁸ Department of Psychiatry, Hospital Clinic, IDIBAPS, Centro de Investigación
497 Biomédica en Red de Salud Mental (CIBERSAM), Universidad de Barcelona,
498 C/Villarroel 170, escalera 9, planta 6, 08036 Barcelona, Spain

499 ⁹ Department of Psychiatry, School of Medicine, Universidad de Valencia, Centro de
500 Investigación Biomédica en Red de Salud Mental (CIBERSAM), C/Avda. Blasco
501 Ibáñez 15, 46010 Valencia, Spain

502 ¹⁰ Department of Medicine, Psychiatry Area, School of Medicine, Universidad de
503 Oviedo, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM),
504 C/Julián Clavería s/n, 33006 Oviedo, Spain

505 ¹¹ Department of Psychiatry, Servicio de Psiquiatría Hospital “Virgen de la Luz”,
506 C/Hermanidad de Donantes de Sangre, 16002 Cuenca, Spain

507 ¹² Department of Psychiatry, Early Psychosis Section, Academic Medical Centre,
508 University of Amsterdam, Meibergdreef 5, 1105 AZ Amsterdam, The Netherlands

509 ¹³ Rivierduinen Centre for Mental Health, Leiden, Sandifortdreef 19, 2333 ZZ Leiden,
510 The Netherlands

511 ¹⁴ Department of Psychiatry and Neuropsychology, School for Mental Health and
512 Neuroscience, South Limburg Mental Health Research and Teaching Network,
513 Maastricht University Medical Centre, P.O. Box 616, 6200 MD Maastricht, The
514 Netherlands

515 ¹⁵ AP-HP, Groupe Hospitalier “Mondor”, Pôle de Psychiatrie, 51 Avenue de Maréchal
516 de Lattre de Tassigny, 94010 Créteil, France

517 ¹⁶ INSERM, U955, Equipe 15, 51 Avenue de Maréchal de Lattre de Tassigny, 94010
518 Créteil, France

519 ¹⁷ Faculté de Médecine, Université Paris-Est, 51 Avenue de Maréchal de Lattre de
520 Tassigny, 94010 Créteil, France

- 521 ¹⁸ Fondation Fondamental, 40 Rue de Mesly, 94000 Créteil, France
- 522 ¹⁹ CMP B CHU, BP 69, 63003 Clermont Ferrand, Cedex 1, France
- 523 ²⁰ Etablissement Public de Santé Maison Blanche, Paris, France
- 524 ²¹ Université Clermont Auvergne, EA 7280, Clermont-Ferrand, 63000, France
- 525 ²² Department of Experimental Biomedicine and Clinical Neuroscience, Section of
- 526 Psychiatry, University of Palermo, Via G. La Loggia n.1, 90129 Palermo, Italy
- 527 ²³ Unit of Psychiatry, "P. Giaccone" General Hospital, Via G. La Loggia n.1, 90129
- 528 Palermo, Italy
- 529 ²⁴ Departamento de Neurociências e Ciências do Comportamento, Faculdade de
- 530 Medicina de Ribeirão Preto, Universidade de São Paulo, Av. Bandeirantes, 3900 -
- 531 Monte Alegre- CEP 14049-900, Ribeirão Preto, SP, Brasil
- 532 ²⁵ Núcleo de Pesquisa em Saúde Mental Populacional, Universidade de São Paulo,
- 533 Avenida Doutor Arnaldo 455, CEP 01246-903, SP, Brasil
- 534 ²⁶ Section of Psychiatry, Department of Neuroscience, Biomedicine and Movement,
- 535 University of Verona, Piazzale L.A. Scuro 10, 37134 Verona, Italy
- 536 ²⁷ Department of Medical and Surgical Science, Psychiatry Unit, Alma Mater
- 537 Studiorum Università di Bologna, Viale Pepoli 5, 40126 Bologna, Italy
- 538 ²⁸ Division of Psychological Medicine and Clinical Neurosciences, MRC Centre for
- 539 Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff CF24 4HQ, UK
- 540

541 **Conflicts of interest**

542 None.

543

544 **References**

- 545 **Addington, J. & Addington, D.** (2007). Patterns, predictors and impact of
- 546 substance use in early psychosis: a longitudinal study. *Acta Psychiatrica*
- 547 *Scandinavica* **115**, 304-309.
- 548 **Barrowclough, C., Gregg, L., Lobban, F., Bucci, S. & Emsley, R.** (2015). The
- 549 impact of cannabis use on clinical outcomes in recent onset psychosis.
- 550 *Schizophrenia Bulletin* **41**, 382-390.

551 **Bernhardson, G. & Gunne, L. M.** (1972). Forty-six cases of psychosis in cannabis
552 abusers. *International Journal of the Addictions* **7**, 9-16.

553 **Bersani, G., Orlandi, V., Kotzalidis, G. D. & Pancheri, P.** (2002). Cannabis and
554 schizophrenia: impact on onset, course, psychopathology and outcomes. *European*
555 *Archives of Psychiatry and Clinical Neuroscience* **252**, 86-92.

556 **Boydell, J., Dean, K., Dutta, R., Giouroukou, E., Fearon, P. & Murray, R.** (2007).
557 A comparison of symptoms and family history in schizophrenia with and without prior
558 cannabis use: implications for the concept of cannabis psychosis. *Schizophrenia*
559 *Research* **93**, 203-210.

560 **Chopra, G. S. & Smith, J. W.** (1974). Psychotic reactions following cannabis use in
561 east indians. *Archives of General Psychiatry* **30**, 24-27.

562 **Di Forti, M., Marconi, A., Carra, E., Fraietta, S., Trotta, A., Bonomo, M., . . .**
563 **Murray, R. M.** (2015). Proportion of patients in south London with first-episode
564 psychosis attributable to use of high potency cannabis: a case-control study. *The*
565 *Lancet Psychiatry* **2**, 233-238.

566 **Di Forti, M., Morgan, C., Dazzan, P., Pariante, C., Mondelli, V., Marques, T. R., . .**
567 **. Murray, R. M.** (2009). High-potency cannabis and the risk of psychosis. *The British*
568 *journal of psychiatry : the journal of mental science* **195**, 488-491.

569 **Di Forti, M., Quattrone, D., Freeman, T. P., Tripoli, G., Gayer-Anderson, C.,**
570 **Quigley, H., . . . van der Ven, E.** (2019). The contribution of cannabis use to
571 variation in the incidence of psychotic disorder across Europe (EU-GEI): a
572 multicentre case-control study. *The Lancet Psychiatry* **6**, 427-436.

573 **Dubertret, C., Bidard, I., Ades, J. & Gorwood, P.** (2006). Lifetime positive
574 symptoms in patients with schizophrenia and cannabis abuse are partially explained
575 by co-morbid addiction. *Schizophrenia Research* **86**, 284-290.

576 **EISohly, M. A., Mehmedic, Z., Foster, S., Gon, C., Chandra, S. & Church, J. C.**
577 (2016). Changes in Cannabis Potency Over the Last 2 Decades (1995-2014):
578 Analysis of Current Data in the United States. *Biological Psychiatry* **79**, 613-619.

579 **European Monitoring Centre for Drugs and Drug Addiction** (2013). *European*
580 *drug report: trends and developments*. Luxembourg: Publications Office of the
581 European Union, 2013.

582 **Ferraro, L., La Cascia, C., Quattrone, D., Sideli, L., Matranga, D., Capuccio, V., .**
583 **. . Di Forti, M.** (2019). Premorbid Adjustment and IQ in Patients With First-Episode
584 Psychosis: A Multisite Case-Control Study of Their Relationship With Cannabis Use.
585 *Schizophrenia Bulletin*.

586 **Ferraro, L., Russo, M., O'Connor, J., Wiffen, B. D., Falcone, M. A., Sideli, L., . . .**
587 **Di Forti, M.** (2013). Cannabis users have higher premorbid IQ than other patients
588 with first onset psychosis. *Schizophrenia Research* **150**, 129-135.

589 **Foti, D. J., Kotov, R., Guey, L. T. & Bromet, E. J.** (2010). Cannabis use and the
590 course of schizophrenia: 10-year follow-up after first hospitalization. *The American*
591 *Journal of Psychiatry* **167**, 987-993.

592 **Freeman, T. P., Groshkova, T., Cunningham, A., Sedefov, R., Griffiths, P. &**
593 **Lynskey, M. T.** (2019). Increasing potency and price of cannabis in Europe, 2006-
594 16. *Addiction* **114**, 1015-1023.

595 **Freeman, T. P., Morgan, C. J., Hindocha, C., Schafer, G., Das, R. K. & Curran, H.**
596 **V.** (2014). Just say 'know': how do cannabinoid concentrations influence users'
597 estimates of cannabis potency and the amount they roll in joints? *Addiction* **109**,
598 1686-1694.

599 **Freeman, T. P., van der Pol, P., Kuijpers, W., Wisselink, J., Das, R. K., Rigter,**
600 **S., . . . Lynskey, M. T.** (2018). Changes in cannabis potency and first-time

601 admissions to drug treatment: a 16-year study in the Netherlands. *Psychological*
602 *Medicine*, 1-7.

603 **Grech, A., Van Os, J., Jones, P. B., Lewis, S. W. & Murray, R. M.** (2005).
604 Cannabis use and outcome of recent onset psychosis. *European psychiatry : the*
605 *journal of the Association of European Psychiatrists* **20**, 349-353.

606 **Green, A. I., Tohen, M. F., Hamer, R. M., Strakowski, S. M., Lieberman, J. A.,**
607 **Glick, I., . . . Group, H. R.** (2004). First episode schizophrenia-related psychosis and
608 substance use disorders: acute response to olanzapine and haloperidol.
609 *Schizophrenia Research* **66**, 125-135.

610 **Hancock, G. R. & Mueller, R. O.** (2001). Rethinking construct reliability within latent
611 variable systems. In *Structural Equation Modeling: Present and Future : a Festschrift*
612 *in Honor of Karl Jöreskog* (ed. R. Cudek, S. Du Toit and D. Sorbom), pp. 195-216.
613 Scientific Software International, Inc.: Lincolnwood, IL.

614 **Jongsma, H. E., Gayer-Anderson, C., Lasalvia, A., Quattrone, D., Mule, A.,**
615 **Szoke, A., . . . European Network of National Schizophrenia Networks Studying**
616 **Gene-Environment Interactions Work Package, G.** (2018). Treated Incidence of
617 Psychotic Disorders in the Multinational EU-GEI Study. *JAMA Psychiatry* **75**, 36-46.

618 **Large, M. M., Smith, G., Sara, G., Paton, M. B., Kedzior, K. K. & Niessen, O. B.**
619 (2012). Meta-analysis of self-reported substance use compared with laboratory
620 substance assay in general adult mental health settings. *International journal of*
621 *methods in psychiatric research* **21**, 134-148.

622 **Mallett, R.** (1997). Sociodemographic schedule. *Section of Social Psychiatry,*
623 *Institute of Psychiatry* **183**.

624 **Marconi, A., Di Forti, M., Lewis, C. M., Murray, R. M. & Vassos, E.** (2016). Meta-
625 analysis of the Association Between the Level of Cannabis Use and Risk of
626 Psychosis. *Schizophrenia Bulletin* **42**, 1262-1269.

627 **McGuffin, P., Farmer, A. & Harvey, I.** (1991). A polydiagnostic application of
628 operational criteria in studies of psychotic illness. Development and reliability of the
629 OPCRIT system. *Archives of General Psychiatry* **48**, 764-770.

630 **McGuire, P., Robson, P., Cubala, W. J., Vasile, D., Morrison, P. D., Barron, R., . . .**
631 **. Wright, S.** (2018). Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia:
632 A Multicenter Randomized Controlled Trial. *The American Journal of Psychiatry* **175**,
633 225-231.

634 **Morrison, P., Zois, V., McKeown, D., Lee, T., Holt, D., Powell, J., . . . Murray, R.**
635 (2009). The acute effects of synthetic intravenous Δ 9-tetrahydrocannabinol on
636 psychosis, mood and cognitive functioning. *Psychological Medicine* **39**, 1607-1616.

637 **Murray, R. M., Englund, A., Abi-Dargham, A., Lewis, D. A., Di Forti, M., Davies,**
638 **C., . . . D'Souza, D. C.** (2017). Cannabis-associated psychosis: Neural substrate and
639 clinical impact. *Neuropharmacology* **124**, 89-104.

640 **Muthén, L. & Muthén, B.** (2012). *Mplus user's guide (Seventh Edition)*. Muthén &
641 Muthén: Los Angeles, CA.

642 **Negrete, J. C., Knapp, W. P., Douglas, D. E. & Smith, W. B.** (1986). Cannabis
643 affects the severity of schizophrenic symptoms: results of a clinical survey.
644 *Psychological Medicine* **16**, 515-520.

645 **Peralta, V. & Cuesta, M. J.** (1992). Influence of cannabis abuse on schizophrenic
646 psychopathology. *Acta Psychiatrica Scandinavica* **85**, 127-130.

647 **Potter, D. J., Hammond, K., Tuffnell, S., Walker, C. & Di Forti, M.** (2018). Potency
648 of Delta(9) -tetrahydrocannabinol and other cannabinoids in cannabis in England in
649 2016: Implications for public health and pharmacology. *Drug testing and analysis* **10**,
650 628-635.

651 **Quattrone, D., Di Forti, M., Gayer-Anderson, C., Ferraro, L., Jongsma, H. E.,**
652 **Tripoli, G., . . . Reininghaus, U.** (2019). Transdiagnostic dimensions of
653 psychopathology at first episode psychosis: findings from the multinational EU-GEI
654 study. *Psychological Medicine* **49**, 1378-1391.

655 **Ragazzi, T. C. C., Shuhama, R., Menezes, P. R. & Del-Ben, C. M.** (2018).
656 Cannabis use as a risk factor for psychotic-like experiences: A systematic review of
657 non-clinical populations evaluated with the Community Assessment of Psychic
658 Experiences. *Early intervention in psychiatry* **12**, 1013-1023.

659 **Ringen, P. A., Nesvag, R., Helle, S., Lagerberg, T. V., Lange, E. H., Loberg, E.**
660 **M., . . . Melle, I.** (2016). Premorbid cannabis use is associated with more symptoms
661 and poorer functioning in schizophrenia spectrum disorder. *Psychological Medicine*
662 **46**, 3127-3136.

663 **Rodriguez, A., Reise, S. P. & Haviland, M. G.** (2016). Applying Bifactor Statistical
664 Indices in the Evaluation of Psychological Measures. *Journal of personality*
665 *assessment* **98**, 223-237.

666 **Ruiz-Veguilla, M., Callado, L. F. & Ferrin, M.** (2012). Neurological soft signs in
667 patients with psychosis and cannabis abuse: a systematic review and meta-analysis
668 of paradox. *Current pharmaceutical design* **18**, 5156-5164.

669 **Schoeler, T., Petros, N., Di Forti, M., Klamerus, E., Foglia, E., Ajnakina, O., . . .**
670 **Bhattacharyya, S.** (2016). Effects of continuation, frequency, and type of cannabis
671 use on relapse in the first 2 years after onset of psychosis: an observational study.
672 *The Lancet Psychiatry* **3**, 947-953.

673 **Schubart, C. D., Sommer, I. E., van Gastel, W. A., Goetgebuer, R. L., Kahn, R. S.**
674 **& Boks, M. P.** (2011). Cannabis with high cannabidiol content is associated with
675 fewer psychotic experiences. *Schizophrenia Research* **130**, 216-221.

676 **Seddon, J. L., Birchwood, M., Copello, A., Everard, L., Jones, P. B., Fowler, D., .**
677 **. . Singh, S. P.** (2016). Cannabis Use Is Associated With Increased Psychotic
678 Symptoms and Poorer Psychosocial Functioning in First-Episode Psychosis: A
679 Report From the UK National EDEN Study. *Schizophrenia Bulletin* **42**, 619-625.

680 **Spencer, D. J.** (1971). Cannabis-Induced Psychosis. *International Journal of the*
681 *Addictions* **6**, 323-326.

682 **StataCorp, L.** (2015). Stata Statistical Software: Release 14 [computer program].
683 *StataCorp LP*.

684 **Stefanis, N. C., Hanssen, M., Smirnis, N. K., Avramopoulos, D. A., Evdokimidis,**
685 **I. K., Stefanis, C. N., . . . Van Os, J.** (2002). Evidence that three dimensions of
686 psychosis have a distribution in the general population. *Psychological Medicine* **32**,
687 347-358.

688 **Stirling, J., Lewis, S., Hopkins, R. & White, C.** (2005). Cannabis use prior to first
689 onset psychosis predicts spared neurocognition at 10-year follow-up. *Schizophrenia*
690 *Research* **75**, 135-137.

691 **Talbott, J. A. & Teague, J. W.** (1969). Marijuana psychosis. Acute toxic psychosis
692 associated with the use of Cannabis derivatives. *Jama* **210**, 299-302.


693 **Taylor, M., Sullivan, J., Ring, S. M., Macleod, J. & Hickman, M.** (2017).
694 Assessment of rates of recanting and hair testing as a biological measure of drug
695 use in a general population sample of young people. *Addiction* **112**, 477-485.

696 **Thornicroft, G., Meadows, G. & Politi, P.** (1992). Is "cannabis psychosis" a distinct
697 category? *European psychiatry : the journal of the Association of European*
698 *Psychiatrists* **7**, 277-282.

699 **Tosato, S., Lasalvia, A., Bonetto, C., Mazzoncini, R., Cristofalo, D., De Santi, K.,**
700 **. . . Group, P.-V.** (2013). The impact of cannabis use on age of onset and clinical

701 characteristics in first-episode psychotic patients. Data from the Psychosis Incident
702 Cohort Outcome Study (PICOS). *Journal of psychiatric research* **47**, 438-444.
703 **van Dijk, D., Koeter, M. W., Hijman, R., Kahn, R. S. & van den Brink, W.** (2012).
704 Effect of cannabis use on the course of schizophrenia in male patients: a prospective
705 cohort study. *Schizophrenia Research* **137**, 50-57.
706 **Walter Bromberg** (1934). Marihuana intoxication. *The American journal of*
707 *psychiatry* **91**, 303-330.
708 **Wolford, G. L., Rosenberg, S. D., Drake, R. E., Mueser, K. T., Oxman, T. E.,**
709 **Hoffman, D., . . . Carrieri, K. L.** (1999). Evaluation of methods for detecting
710 substance use disorder in persons with severe mental illness. *Psychology of*
711 *Addictive Behaviors* **13**, 313-326.
712 **Zammit, S., Moore, T. H., Lingford-Hughes, A., Barnes, T. R., Jones, P. B.,**
713 **Burke, M. & Lewis, G.** (2008). Effects of cannabis use on outcomes of psychotic
714 disorders: systematic review. *The British journal of psychiatry : the journal of mental*
715 *science* **193**, 357-363.
716

Figure 1. Bifactor model of psychotic experiences in controls



(□) Observed variables (No. of CAPE items); (○) Unobserved variables (latent factors); (→) standardized item loading estimation onto latent factors; G, general psychosis-like factor; Specific psychotic experiences factors: DEP, Depression; NEG, Negative; POS, Positive. Reliability and strength estimates: H=construct reliability index; ω = McDonald omega; ω_H =hierarchical omega; ω/ω_H = Relative omega.

Explanatory note: McDonald's ω is an estimate of the proportion of the common variance accounted by general and specific symptom dimensions. (Rodriguez *et al.*, 2016). Relative omega (ω/ω_H) is the amount of reliable variance explained in the observed scores attributable to a) the general factor independently from the specific symptom dimensions, and 2) each specific symptom dimension independently from the general factor.

H is an index of the quality of the measurement model based on the set of CAPE items for each dimension. (Hancock and Mueller, 2001) Indices can range from 0 to 1, with values closer to 1 indicating a better construct reliability and replicability across studies.

Figure 2. Positive symptom dimension in cases by patterns of cannabis use.




Figure 2 shows the contrasts of the positive symptom dimension predicted mean of each group of patterns of use of cannabis against the predicted grand mean of all groups (represented by the red line). The positive value for the contrast of the daily use of high potency cannabis indicates more positive symptomatology in this group. On the other hand, negative values for the contrasts of the first two groups indicates less positive symptomatology when there is less exposure to cannabis. These differences are statistically significant, as indicated by 95% confidence intervals that do not overlap with zero. The model was a random intercept model which allowed symptoms to vary across countries and sites within countries, but it assumed that frequency of use and type of cannabis had an individual fixed effect. Values were adjusted for age, sex, ethnicity, diagnosis, and use of other recreational/illicit substances.

Figure 3. Negative symptom dimension in cases by patterns of cannabis use.





Figure 3 shows the contrasts of the negative symptom dimension predicted mean of each group of patterns of use of cannabis against the grand adjusted predicted mean (represented by the red line). Subjects who had never used cannabis presented with more negative symptoms compared to the whole sample. The model was a random intercept model which allowed symptoms to vary across countries and sites within countries, but it assumed that frequency of use and type of cannabis had an individual fixed effect.

Figure 1. Bifactor model of psychotic experiences in controls



(□) Observed variables (No. of CAPE items); (○) Unobserved variables (latent factors); (→) standardized item loading estimation onto latent factors; G, general psychosis-like factor; Specific psychotic experiences factors: DEP, Depression; NEG, Negative; POS, Positive. Reliability and strength estimates: H=construct reliability index; ω = McDonald omega; ω_H =hierarchical omega; ω/ω_H = Relative omega.
 Explanatory note: McDonald's ω is an estimate of the proportion of the common variance accounted by general and specific symptom dimensions. (Rodriguez *et al.*, 2016). Relative omega (ω/ω_H) is the amount of reliable variance explained in the observed scores attributable to a) the general factor independently from the specific symptom dimensions, and 2) each specific symptom dimension independently from the general factor.
 H is an index of the quality of the measurement model based on the set of CAPE items for each dimension. (Hancock and Mueller, 2001) Indices can range from 0 to 1, with values closer to 1 indicating a better construct reliability and replicability across studies.

Figure 2. Positive symptom dimension in cases by patterns of cannabis use.




Figure 2 shows the contrasts of the positive symptom dimension predicted mean of each group of patterns of use of cannabis against the predicted grand mean of all groups (represented by the red line). The positive value for the contrast of the daily use of high potency cannabis indicates more positive symptomatology in this group. On the other hand, negative values for the contrasts of the first two groups indicates less positive symptomatology when there is less exposure to cannabis. These differences are statistically significant, as indicated by 95% confidence intervals that do not overlap with zero. The model was a random intercept model which allowed symptoms to vary across countries and sites within countries, but it assumed that frequency of use and type of cannabis had an individual fixed effect. Values were adjusted for age, sex, ethnicity, diagnosis, and use of other recreational/illicit substances.

Figure 3. Negative symptom dimension in cases by patterns of cannabis use.




Figure 3 shows the contrasts of the negative symptom dimension predicted mean of each group of patterns of use of cannabis against the grand adjusted predicted mean (represented by the red line). Subjects who had never used cannabis presented with more negative symptoms compared to the whole sample. The model was a random intercept model which allowed symptoms to vary across countries and sites within countries, but it assumed that frequency of use and type of cannabis had an individual fixed effect.

Table 1.1 Symptom dimensions in FEP patients by measures of cannabis use^a

Symptom dimension	Ever used cannabis B (95% CI)	Current use of cannabis B (95% CI)	Age at first use of cannabis B (95% CI)	Money used for cannabis B (95% CI)
Positive	0.16* (0 to 0.31)	0.21* (0.04 to 0.37)	0.05 (-0.13 to 0.22)	0.3** (0.11 to 0.48)
Negative	-0.22** (-0.37 to -0.07)	-0.09 (-0.26 to 0.07)	0.07 (-0.09 to 0.22)	0.07 (-0.12 to 0.25)
Depressive	-0.08 (-0.24 to 0.08)	-0.08 (-0.22 to 0.06)	-0.09 (-0.23 to 0.05)	-0.11 (-0.29 to 0.06)
Disorganization	-0.01 (-0.24 to 0.03)	0.01 (-0.05 to 0.26)	0.11 (-0.06 to 0.28)	0.1 (-0.17 to 0.19)
Manic	0.22** (0.08 to 0.36)	0.12 (-0.02 to 0.27)	-0.09 (-0.25 to 0.07)	0.05 (-0.11 to 0.22)
General factor	0.05 (-0.06 to 0.17)	0.02 (-0.1 to 0.14)	-0.06 (-0.09 to 0.22)	0.03 (-0.11 to 0.17)

^aAll models were adjusted for age, sex, ethnicity, use of other recreational/illicit substances, and diagnosis. Models were random-intercept models that included two random effects to allow symptomatology to vary across countries and across sites within countries but assumed that individual-level exposure to cannabis had a fixed effect across the entire sample.

Significance: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$; associations that survived after Benjamini-Hochberg correction are showed in bold.

Table 1.2 Psychotic experience dimensions in controls by cannabis use^a

Psychotic experience dimension	Ever used cannabis B (95% CI)	Current use of cannabis B (95% CI)	Age at first use of cannabis B (95% CI)	Money used for cannabis B (95% CI)
Positive	0.05 (-0.06 to 0.17)	0.33*** (0.15 to 0.51)	0.08 (-0.11 to 0.25)	0.39* (0.09 to 0.69)
Negative	0.11 (-0.01 to 0.24)	0.16 (-0.03 to 0.36)	-0.11 (-0.29 to 0.07)	-0.12 (-0.2 to 0.44)
Depressive	0.09 (-0.03 to 0.21)	0.01 (-0.19 to 0.20)	-0.02 (-0.21 to 0.16)	-0.02 (-0.3 to 0.35)
General factor	0.04 (-0.08 to 0.17)	0.13 (-0.07 to 0.33)	0.08 (-0.11 to 0.22)	0.15 (-0.18 to 0.48)

^aAll models were adjusted for age, sex, ethnicity, and use of other recreational/illicit substances. Models were random-intercept models that included two random effects to allow symptomatology to vary across countries and across sites within countries but assumed that individual-level exposure to cannabis had a fixed effect across the entire sample.

Significance: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$; associations that survived after Benjamini-Hochberg correction are showed in bold.

SUPPLEMENTARY MATERIAL

Supplementary Table S1. Socio-demographic characteristics and history of substance misuse of the analysed sample

	FEP N=901	Controls N=1235
Age (mean; SD)	30.8 (10.5)	36.1 (13.3)
Sex (male %; N)	61.9 (558)	47 (581)
Self-reported Ethnicity		
White (%; N)	59.05 (532)	75.22 (929)
Black	18.65 (168)	9.55 (118)
Mixed	11.54 (104)	9.15 (113)
Asian	3.55 (32)	2.67 (33)
North African	4.66 (42)	1.86 (23)
Others	2.55 (23)	1.54 (19)
Ever used cannabis		
Yes (%;N)	64.93 (585)	46.48 (574)
Missing	1.44 (13)	1.05 (13)
Current use of cannabis		
Yes (%;N)	21.64 (195)	10.61 (131)
Missing	1.78 (16)	1.05 (13)
Age at first use of cannabis		
Never Used (%; N)	33.63 (303)	52.47 (648)
<=15 year old	27.75 (250)	13.52 (167)
16 year old and older	35.74 (322)	32.96 (407)
Missing	2.89 (26)	1.05 (13)
Money used for cannabis (weekly)		
From 0 to 20 euro	76.47 (689)	92.3 (1,140)
More than 20 euro	16.1 (145)	3.16 (39)
Missing	7.44 (67)	4.53 (56)
Lifetime frequency of use		
Never use	56.83 (512)	52.47 (648)
Less than daily	11.54 (104)	39.68 (490)
Daily	28.86 (260)	6.72 (83)
Missing	2.77 (25)	1.13 (14)
Type of cannabis		
Never used	33.63 (303)	55.57 (648)
Less than 10% THC	26.64 (240)	23.89 (295)
More than 10% THC	32.63 (294)	18.06 (223)
Missing	7.1 (64)	5.59 (69)
Current tobacco use		

>10 cigarettes x day (%;N)	28.71 (262)	10.85 (134)
Missing	3.77 (34)	1.94 (24)
Current use of other drugs		
Stimulants (%;N)	8.62 (82)	4.53 (56)
Missing	1.6 (15)	1.05 (13)
Hallucinogens	5.23 (49)	2.02 (25)
Missing	1.92 (18)	1.21 (15)
Ketamine	2.13 (20)	1.05 (13)
Missing	1.92 (18)	1.21(15)
Novel Psychoactive Substances	1.39 (13)	0.65 (8)
Missing	1.71 (16)	1.05 (13)
Crack	2.67 (25)	2 (0.16)
Missing	1.6 (15)	1.05 (13)
Cocaine	14.94 (140)	5.83 (72)
Missing	1.81 (17)	1.13 (14)
Current alcohol overuse		
Drinks =>10 units per week (%;N)	10.88 (98)	12.47 (154)
Missing	11.4(103)	3.24(40)
Diagnosis		
Schizophrenia (%;N)	13.2 (282)	
Schizoaffective disorders	17.84 (381)	
Bipolar Disorders	2.48 (53)	
Psychotic Depression	1.92 (41)	
Unspecified Psychosis	6.74 (144)	

Supplementary table S2. Cannabis measures in the EU-GEI study

Lifetime cannabis use	0= <i>never used</i>	1=Yes	
Currently using cannabis	0= <i>no use at the time of recruitment in the study and over the previous 4 weeks</i>	1=Yes	
Age at first use of cannabis	0= <i>started at age 16 years or older</i>	1= <i>started at age 15 years or younger</i>	
Lifetime frequency of use	0= <i>never used</i>	1= <i>used less than daily</i>	2= <i>used daily</i>
Money spent weekly on cannabis	0= <i>never used or spent 20 EURO or less per week</i>	1= <i>spent more than 20 EURO per week</i>	
Type of cannabis used¹	0= <i>never used</i>	1= <i>types with THC<10%</i>	2= <i>types with THC=>10%</i>

¹*Explanatory note: The potency variable was defined by a cut off of 10% of the THC concentration expected in the different varieties of cannabis in each catchment area, based on government and national data examined by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (European Monitoring Centre for Drugs and Drug Addiction, 2013, Di Forti et al., 2019).*

Cannabis varieties classified as low-potency (THC<10%) were: hash/resin from UK and Italy, imported herbal cannabis from UK, Italy, Spain and France, Brazilian marijuana and hash and the Dutch Geimporteerde Wiet.

Cannabis varieties classified as high-potency (THC>10%) were: UK home-grown skunk/sensimilla UK Super Skunk, Italian home-grown skunk/sensimilla, Italian Super Skunk, the Dutch Nederwiet,


Nederhasj and geïmporteerde hasj, the Spanish and French Hashish (from Morocco), Spanish home-grown sensimilla, French home-grown skunk/sensimilla/super-skunk and Brazilian skunk.

Supplementary table S3. Prevalence of CAPE psychotic experiences in population controls


CAPE ITEM	Item no.	Factor	Valid frequency Total sample
<i>Do you ever feel as if people seem to drop hints about you or say things with a double meaning?</i>	2	POS	50.9% (629)
<i>Do you ever feel as if things in magazines or on TV were written especially for you?</i>	5	POS	17.6% (217)
<i>Do you ever feel as if some people are not what they seem to be?</i>	6	POS	74.7% (923)
<i>Do you ever feel as if you are being persecuted in some way?</i>	7	POS	18.9% (233)
<i>Do you ever feel as if there is a conspiracy against you?</i>	10	POS	12.4% (153)
<i>Do you ever feel as if you are destined to be someone very important?</i>	11	POS	30.6% (378)
<i>Do you ever feel that you are a very special or unusual person?</i>	13	POS	35.5% (438)
<i>Do you ever think that people can communicate telepathically?</i>	15	POS	25.6% (316)
<i>Do you ever feel as if electrical devices such as computers can influence the way you think?</i>	17	POS	11.2% (138)
<i>Do you believe in the power of witchcraft, voodoo or the occult?</i>	20	POS	27.3% (337)
<i>Do you ever feel that people look at you oddly because of your appearance?</i>	22	POS	34.2% (422)
<i>Do you ever feel as if the thoughts in your head are being taken away from you?</i>	24	POS	3.9% (48)
<i>Do you ever feel as if the thoughts in your head are not your own?</i>	26	POS	7.3% (90)
<i>Have your thoughts ever been so vivid that you were worried other people would hear them?</i>	28	POS	10.6% (131)
<i>Do you ever hear your own thoughts being echoed back to you?</i>	30	POS	9.1% (112)
<i>Do you ever feel as if you are under the control of some force or power other than yourself?</i>	31	POS	5.3% (66)
<i>Do you ever hear voices when you are alone?</i>	33	POS	6.8% (84)
<i>Do you ever hear voices talking to each other when you are alone?</i>	34	POS	1.9% (23)
<i>Do you ever feel that you are not a very animated person?</i>	3	NEG	44.8% (553)
<i>Do you ever feel that you are not much of a talker when you are conversing with other people?</i>	4	NEG	51.8% (640)
<i>Do you ever feel that you experience few or no emotions at important events?</i>	8	NEG	38.1% (470)
<i>Do you ever feel that you have no interest to be with other people?</i>	16	NEG	50.2% (620)
<i>Do you ever feel that you are lacking in motivation to do things?</i>	18	NEG	67.2% (830)
<i>Do you ever feel that you are lacking in energy?</i>	21	NEG	70.9% (876)
<i>Do you ever feel that your mind is empty?</i>	23	NEG	24.6% (304)
<i>Do you ever feel that you are spending all your days doing nothing?</i>	25	NEG	42.6% (526)
<i>Do you ever feel that your feelings are lacking in intensity?</i>	27	NEG	26.2% (323)
<i>Do you ever feel that you are lacking in spontaneity?</i>	29	NEG	39.6% (489)
<i>Do you ever feel that your emotions are blunted?</i>	32	NEG	31% (383)
<i>Do you ever feel that you are neglecting your appearance or personal hygiene?</i>	35	NEG	27.3% (337)
<i>Do you ever feel that you can never get things done?</i>	36	NEG	55.1% (680)
<i>Do you ever feel that you have only few hobbies or interests?</i>	37	NEG	36.4% (450)
<i>Do you ever feel sad?</i>	1	DEP	93.7% (1,157)
<i>Do you ever feel pessimistic about everything?</i>	9	DEP	48.8% (603)
<i>Do you ever feel as if there is no future for you?</i>	12	DEP	27.5% (340)
<i>Do you ever feel as if you do not want to live anymore?</i>	14	DEP	24.9% (308)
<i>Do you ever cry about nothing?</i>	19	DEP	34.9% (431)
<i>Do you ever feel guilty?</i>	38	DEP	73.4% (907)
<i>Do you ever feel like a failure?</i>	39	DEP	48.1% (594)
<i>Do you ever feel tense?</i>	40	DEP	81.2% (1,003)

Supplementary Figure S1
Path diagrams of the five psychotic experiences' models


Model A




Model B




Model C



Model D



Model E



Explanatory note: (□) Observed symptoms (CAPE items); (○) Unobserved variables (latent factors); (→) item loading on latent factors; (ε) item error variance. CAPE item numbers are shown in Tables S1; for simplicity, only three items for each latent factor are presented in the diagrams.

Explanatory note: *Model A*: unidimensional model with one unique general factor; *Model B*: multidimensional model with three uncorrelated specific factors; *Model C*: multidimensional model with three correlated specific factors; *Model D*: bifactor model with one general factor and three

uncorrelated specific factors; Model *E*: hierarchical model with three correlated first-order specific factors and one general second-order factor.

As showed in the main text and in Table 1, the bifactor model for the CAPE (Model D) best reflected the dimensional structure of psychosis in population controls when compared with the other models. This is consistent with our previous findings on the bifactor model for the OPCRIT in patients (Quattrone *et al.*, 2019). The bifactor model allows examining the variance due to each dimension whilst partitioning out the variance due to the common item effect of the whole symptomatology. Thus, in this study, we performed the best possible evaluation of the impact of cannabis use on specific subsets of psychotic symptoms or experiences in patients and controls.

Supplementary Table S4. Model fit statistics of unidimensional, multidimensional, bifactor, second-order models for psychotic experiences and for psychotic symptoms

CAPE (CONTROLS)				
	Full information fit statistics ^a			
	LL	AIC	BIC	SABIC
A - Unidimensional Model	-23638	47397	47715	47524
B - Multidimensional Model (five uncorrelated factors)	-23844	47808	48126	47936
C - Multidimensional Model (five correlated factors)	-23341	46808	47142	46942
D - Bifactor Model (one general factor and five specific uncorrelated factors)	-23139	46458	46935	46649
E - Hierarchical Model (five first-order specific correlated factors and one second order general factor)	-23341	46807	47135	46938
OPCRIT (PATIENTS) (Quattrone <i>et al.</i> , 2019)				
	Full information fit statistics ^a			
	LL	AIC	BIC	SABIC
A - Unidimensional Model	-29965	60126	60618	60306
B - Multidimensional Model (five uncorrelated factors)	-28070	56335	56826	56515
C - Multidimensional Model (five correlated factors)	-27894	56004	56546	56202
D - Bifactor Model (one general factor and five specific uncorrelated factors)	-27597	55489	56226	55759
E - Hierarchical Model (five first-order specific correlated factors and one second order general factor)	-27995	56197	56713	56386

LL, log-likelihood; AIC, Akaike Information Criterion; BIC, Bayesian Information Criterion; SABIC Sample-size Adjusted Bayesian Information Criterion

A difference of 10 in AIC, BIC and SABIC is considered important. Lower values indicate a statistically better model fit (best values across models are indicated in bold).

Supplementary Table S5. Prevalence of OPCRIT symptoms in patients (Quattrone *et al.*, 2019)

OPCRIT ITEM	Item no.	Factor	Valid frequency
Persecutory Delusions	54	POS	71.6% (794)
Well organised delusions	55	POS	41.6% (458)
Delusions of influence	58	POS	24.1% (267)
Bizarre Delusions	59	POS	23.3% (259)
Widespread Delusions	60	POS	42.4% (437)
Delusions of passivity	61	POS	15.2% (168)
Primary delusional perception	62	POS	26.2% (286)
Other primary delusions	63	POS	19.4% (213)
Delusions & hallucinations last for one week	64	POS	47.9% (495)
Persecutory delusions & hallucinations	65	POS	30.1% (311)
Thought insertion	66	POS	16.4% (180)
Thought broadcast	68	POS	15.5% (171)
Third person auditory hallucinations	73	POS	29.3% (322)
Running commentary voices	74	POS	24.1% (266)
Abusive/accusatory/persecutory voices	75	POS	31.8% (329)
Other (non-affective) auditory hallucinations	76	POS	23.3% (264)
Non-affective hallucination in any modality	77	POS	26.7% (294)

Negative formal thought disorder	29	NEG	19% (209)
Restricted affect	32	NEG	36.4% (404)
Blunted affect	33	NEG	21.9% (243)
Bizarre behaviour	17	DIS	44.9% (496)
Speech difficult to understand	26	DIS	20.9% (230)
Incoherent	27	DIS	13% (13)
Positive formal thought disorder	28	DIS	24.3% (268)
Inappropriate affect	34	DIS	19.6% (216)
Excessive activity	19	MAN	25.5% (283)
Reckless activity	20	MAN	21% (233)
Distractibility	21	MAN	47.4% (521)
Reduced need for sleep	22	MAN	30.8% (340)
Agitated activity	23	MAN	41.3% (457)
Pressured speech	30	MAN	23% (255)
Thoughts racing	31	MAN	33% (365)
Elevated mood	35	MAN	20.6% (229)
Irritable mood	36	MAN	47.7% (529)
Increased self esteem	56	MAN	24.1% (267)
Grandiose Delusions	57	MAN	23.3% (259)
Slowed activity	24	DEP	23.6% (261)
Loss of energy/tiredness	25	DEP	40.1% (444)
Dysphoria	37	DEP	48.7% (540)
Loss of pleasure	39	DEP	43.2% (477)
Poor concentration	41	DEP	61% (676)
Excessive self-reproach	42	DEP	25.8% (286)
Suicidal ideation	43	DEP	34.2% (380)
Initial insomnia	44	DEP	52.4% (576)
Middle insomnia (broken sleep)	45	DEP	38.4% (423)
Early morning waking	46	DEP	24.9% (274)
Excessive sleep	47	DEP	15.2% (168)
Poor appetite	48	DEP	37% (407)
Weight Loss	49	DEP	29.3% (315)

Supplementary Table S6.1. Symptom dimensions in patients by frequency of use and potency of cannabis^a

Model	Lifetime frequency of use B (95% CI)		Potency of cannabis B (95% CI)	
	Less than daily (<i>v. never used</i>)	Daily (<i>v. never used</i>)	low potency (<i>v. no use</i>)	high potency (<i>v. no use</i>)
Positive symptom dimension	0.1 (-0.21 to 0.22)	0.23** (0.07 to 0.39)	0.09 (-0.12 to 0.28)	0.22** (0.02 to 0.29)
Negative symptom dimension	-0.07 (-0.29 to 0.15)	-0.09 (-0.26 to 0.09)	-0.24** (-0.41 to -0.06)	-0.2* (-0.39 to -0.02)
Depressive symptom dimension	-0.12 (-0.31 to 0.06)	-0.1 (-0.24 to 0.04)	-0.13 (-0.28 to 0.03)	-0.13 (-0.29 to 0.03)
Disorganization symptom dimension	0.26* (0.05 to 0.47)	0.11 (-0.04 to 0.27)	-0.02 (-0.19 to 0.15)	0.13 (-0.04 to 0.32)
Manic symptom dimension	0.02 (-0.17 to 0.22)	0.13 (-0.02 to 0.28)	0.23** (0.06 to 0.39)	0.27** (0.1 to 0.44)
General Psychosis factor	0.17* (0.01 to 0.33)	0.12* (0.01 to 0.25)	0.06 (-0.07 to 0.19)	0.02 (-0.12 to 0.17)

^aAll models were adjusted for age, sex, ethnicity, current use of other recreational/illicit substances, and diagnosis. Models were random-intercept models that included two random effects to allow symptomatology to vary across countries and across sites within countries but assumed that individual-level exposure to cannabis had a fixed effect across the entire sample.

Significance: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$; associations that hold after Benjamini-Hochberg procedure are showed in bold.


Supplementary Table S6.2. Psychotic experience dimensions in controls by frequency of use and potency of cannabis^a

Model	Lifetime frequency of use B (95% CI)		Potency of cannabis B (95% CI)	
	Less than daily (<i>v. never used</i>)	Daily use (<i>v. rare and never use</i>)	Low Potency <i>v. no use</i>	High potency <i>v. no use</i>
Positive psychotic experience dimension	0.04 (-0.08 to 0.16)	0.17 (-0.05 to 0.38)	0.08 (-0.06 to 0.22)	0.03 (-0.13 to 0.19)
Negative experience dimension	0.11 (-0.02 to 0.24)	0.14 (-0.09 to 0.38)	0.09 (-0.05 to 0.24)	0.12 (-0.05 to 0.29)
Depressive experience dimension	0.08 (-0.05 to 0.2)	0.17 (-0.08 to 0.4)	0.08 (-0.07 to 0.23)	0.05 (-0.11 to 0.22)
General psychotic experience factor	0.03 (-0.1 to 0.16)	0.13 (-0.11 to 0.37)	0.08 (-0.07 to 0.23)	-0.02 (-0.19 to 0.15)

^aAll models were adjusted for age, sex, ethnicity, current use of other recreational/illicit substances. Models were random-intercept models that included two random effects to allow symptomatology to vary across countries and across sites within countries but assumed that individual-level exposure to cannabis had a fixed effect across the entire sample.

Significance: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$

Supplementary Figure S2. Symptom dimensions by frequency of use and potency of cannabis



References

- Di Forti, M., Quattrone, D., Freeman, T. P., Tripoli, G., Gayer-Anderson, C., Quigley, H., . . . van der Ven, E.** (2019). The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. *The Lancet Psychiatry* **6**, 427-436.
- European Monitoring Centre for Drugs and Drug Addiction** (2013). *European drug report: trends and developments*. Luxembourg: Publications Office of the European Union, 2013.
- Quattrone, D., Di Forti, M., Gayer-Anderson, C., Ferraro, L., Jongsma, H. E., Tripoli, G., . . . Reininghaus, U.** (2019). Transdiagnostic dimensions of psychopathology at first episode psychosis: findings from the multinational EU-GEI study. *Psychol Med* **49**, 1378-1391.